Gujarat Themis Biosyn's bank facilities are under 'Rating Watch with Negative Implications' by CARE due to significant planned acquisitions. The company disputes the rating, citing forward cash flows.
Gujarat Themis Biosyn Faces Rating Watch Negative Amid Major Acquisitions
Gujarat Themis Biosyn Ltd's long-term bank facilities have been placed on 'Rating Watch with Negative Implications' (RWN) by CARE, with the rating agency assigning CARE BBB (RWN). Its short-term facilities were assigned CARE A3+ (RWN).
Reader Takeaway: Aggressive expansion clashes with credit assessment; QIP execution is key.
What just happened
CARE Ratings has placed Gujarat Themis Biosyn Limited's bank facilities on watch due to concerns over the company's substantial planned acquisitions and proposed funding. The rating agency cited an increase in overall gearing to 0.56x in FY26(A) from 0.12x in FY25(A), and a significant decline in interest coverage to 26.09x from 193.27x, primarily due to anticipated higher interest expenses.
Why this matters
This rating action signals increased credit risk for Gujarat Themis Biosyn. It comes as the company plans to acquire MicroBiopharm Japan for approximately ₹1,300 crore and the Sanofi Portfolio for about ₹1,700 crore, funded partly by a proposed ₹1,000 crore Qualified Institutional Placement (QIP). The market will closely watch the execution of this QIP and the overall funding mix for these large deals.
The backstory
Gujarat Themis Biosyn is embarking on a significant inorganic growth path. The acquisitions of MicroBiopharm Japan and the Sanofi brand portfolio are substantial, valued at roughly ten times the company's tangible net worth. The company is also planning to raise capital through a QIP to support these strategic moves.
What changes now
The rating watch implies heightened scrutiny from lenders and investors. Gujarat Themis Biosyn management has formally dissented, arguing the rating is backward-looking and ignores future contracted cash flows from the acquisitions. They believe the rating agency is assessing debt obligations that do not yet exist.
Risks to watch
Key risks include the successful execution of the ₹1,000 crore QIP, which is crucial for the MicroBiopharm Japan acquisition. There are also integration risks associated with absorbing the new entities and brands, and the overall increase in leverage requires careful management to ensure financial stability.
Peer comparison
Specific peer comparison data was not available in the filing. However, companies undertaking large-scale acquisitions typically face similar challenges in funding, integration, and managing increased debt levels. The market reaction will also depend on how peers have managed such expansions.
Context metrics (time-bound)
- Total operating income grew from ₹152.29 crore in FY25(A) to ₹167.23 crore in FY26(A).
- Profit Before Interest, Depreciation, Taxes, and Amortisation (PBILDT) improved to ₹76.94 crore in FY26(A) from ₹70.33 crore in FY25(A).
- Profit After Tax (PAT) moderated to ₹46.68 crore in FY26(A) from ₹48.77 crore in FY25(A) due to rising costs.
- Overall gearing increased to 0.56x in FY26(A) from 0.12x in FY25(A).
- Interest coverage declined to 26.09x in FY26(A) from 193.27x in FY25(A).
What to track next
Investors should monitor the progress of the QIP, regulatory approvals for the acquisitions, and the company's communication regarding its funding strategy. The company's ability to integrate the acquired assets effectively and manage its heightened leverage will be critical.